Spyre Therapeutics (SYRE)
Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.
$86.47
vs last close−5.50 (−5.98%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 41 days
EPS estimate
−$0.80
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.81−$0.74−$0.49−$0.15−$0.70−$0.74−$0.36Pending
Estimate−$0.89−$0.84−$0.73−$0.76−$0.66−$0.66−$0.76−$0.80
Surprise+9.0%+11.9%+32.9%+80.3%−6.1%−12.1%+52.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported————$90.5M——Pending
Estimate$3.0M$4.0M—$2.0M$142.9M———
Surprise————−36.7%———
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.92 | — | — |
| Sep 2027 | −$0.90 | — | — |
| Jun 2027 | −$0.85 | — | — |
| Mar 2027 | −$0.84 | — | — |
| Dec 2026 | −$0.80 | — | — |
| Nov 2026 | −$0.80 | — | — |
| Aug 2026 | −$0.76 | −$0.36 | +52.6% |
| May 2026 | −$0.66 | −$0.74 | −12.1% |
| Feb 2026 | −$0.66 | −$0.70 | −6.1% |
| Nov 2025 | −$0.76 | −$0.15 | +80.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.92 | — | — | $0 | — | — | — |
| Sep 2027 | −$0.90 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.85 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.84 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.80 | — | — | $0 | — | — | — |
| Nov 3, 2026 | −$0.80 | — | — | $0 | — | — | — |
| Aug 4, 2026 | −$0.76 | −$0.36 | +52.6% | — | — | — | −0.6% |
| May 5, 2026 | −$0.66 | −$0.74 | −12.1% | — | — | — | +2.8% |
| Feb 19, 2026 | −$0.66 | −$0.70 | −6.1% | $142.9M | $90.5M | −36.7% | +3.3% |
| Nov 4, 2025 | −$0.76 | −$0.15 | +80.3% | $2.0M | — | — | −0.6% |
| Aug 5, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 28, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Dec 30, 2022 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Sep 29, 2021 | |||||||
| Jun 29, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 30, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 30, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 30, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 30, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 |